Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Meloxicam Tablets (TF4) vs Capsules
NCT02181907Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2003
- Primary completion
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of meloxicam in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration of the analyte in plasma up to 60 hours and Area under the concentration time curve of the analyte in plasma from zero time to 60 hours. Started Mar 2003; status: completed.
02
Drugs
meloxicam
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02181907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181907.